中性粒细胞与淋巴细胞比值的变化可预测曲贝替定治疗软组织肉瘤的疗效。
Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma.
作者信息
Sato Yasuyoshi, Nakano Kenji, Kawaguchi Kuniki, Fukuda Naoki, Wang Xiaofei, Urasaki Tetsuya, Ohmoto Akihiro, Hayashi Naomi, Yunokawa Mayu, Ono Makiko, Tomomatsu Junichi, Hayakawa Keiko, Funauchi Yuki, Tanizawa Taisuke, Ae Keisuke, Matsumoto Seiichi, Takahashi Shunji
机构信息
Department of Medical Oncology,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Orthopedic Oncology,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
出版信息
Cancer Diagn Progn. 2021 Jul 3;1(4):303-308. doi: 10.21873/cdp.10040. eCollection 2021 Sep-Oct.
BACKGROUND/AIM: Trabectedin and eribulin are widely used for the treatment of soft-tissue sarcoma (STS). Previously it was shown that the baseline neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of eribulin for STS. However, prognostic factors for trabectedin on STS have not been identified to date.
PATIENTS AND METHODS
We conducted a retrospective study of data collected prospectively from 39 patients treated with trabectedin for recurrent or metastatic STS between October 2012 and December 2019. To determine the predictive factors of overall survival (OS) and progression-free survival (PFS), univariate and multivariate analyses were performed.
RESULTS
Age ≥40 (HR=0.33, 95% CI=0.15-0.71; p=0.0050) and changes in NLR (ΔNLR) <0.5 (HR=2.40, 95% CI-1.01-5.72; p=0.048) were independent factors predictive of longer OS. In addition, age ≥40 (HR=0.23, 95% CI=0.10-0.52; p<0.001) was an independent predictor of longer PFS.
CONCLUSION
Changes in NLR and age ≥40 years were able to predict the efficacy of trabectedin for STS.
背景/目的：曲贝替定和艾瑞布林被广泛用于治疗软组织肉瘤（STS）。此前有研究表明，基线中性粒细胞与淋巴细胞比值（NLR）可预测艾瑞布林对STS的疗效。然而，迄今为止，尚未确定曲贝替定治疗STS的预后因素。
患者与方法
我们对2012年10月至2019年12月期间接受曲贝替定治疗复发性或转移性STS的39例患者前瞻性收集的数据进行了回顾性研究。为了确定总生存期（OS）和无进展生存期（PFS）的预测因素，进行了单因素和多因素分析。
结果
年龄≥40岁（HR=0.33，95%CI=0.15-0.71；p=0.0050）和NLR变化（ΔNLR）<0.5（HR=2.40，95%CI=1.01-5.72；p=0.048）是预测OS更长的独立因素。此外，年龄≥40岁（HR=0.23，95%CI=0.10-0.52；p<0.001）是PFS更长的独立预测因素。
结论
NLR变化和年龄≥40岁能够预测曲贝替定对STS的疗效。
Zotero 插件